Patents Assigned to Bayer Healthcare AG
  • Use of a novel eimeria gene and corresponding protein
    Publication number: 20070184054
    Abstract: The invention relates to a novel oocyst sporocyst protein (EtOs22) belonging to the parasite of the species Eimeria tenella and to the polynucleotide encoding this protein, to vectors which contain this polynucleotide, to cells which are transformed with these vectors, to antibodies which are directed against the protein, to vaccines which comprise the polynucleotide, the protein, or fragments thereof, the abovementioned vectors or antibodies directed against the protein, and to the use of polynucleotide or of polypeptide for finding active compounds for treating an infection with Eimeria and active compounds which are suitable for the therapy of an infection with Eimeria.
    Type: Application
    Filed: June 30, 2004
    Publication date: August 9, 2007
    Applicant: BAYER HEALTHCARE AG
    Inventors: Gisela Greif, Ralf Hosse, Jurgen Krucken, Frank Wunderlich
  • Bicyclic N-arylamides
    Patent number: 7247728
    Abstract: This application relates to bicyclic N-aryl amides of the formula R1 is a 1-aza-bicyclo[3.2.1]octyl group, a 1-aza-bicyclo[2.2.2]oct-3-yl; R2 is an optionally sustituted 8- to 10- membered heteroaryl, naphthyl, or azulenyl group; and R3 is H or (C1C6)alkyl; or a salt, solvate, or solvate of a salt of these compounds. A process for preparing these compounds, medicaments containing them, and methods for using them in treatment are also disclosed and claimed.
    Type: Grant
    Filed: December 6, 2002
    Date of Patent: July 24, 2007
    Assignee: Bayer Healthcare AG
    Inventors: Joachim Luithle, Frank-Gerhard Böss, Christina Erb, Timo Flessner, Martin Hendrix, Marja van Kampen, Christoph Methfessel
  • Relaxin as an independent risk factor predicting mortality
    Publication number: 20070166757
    Abstract: Disclosed are methods of characterising life expectancy of human individuals on the basis of measured relaxin levels. In one aspect of the invention the human individuals are end-stage-kidney-disease patients.
    Type: Application
    Filed: May 25, 2004
    Publication date: July 19, 2007
    Applicant: Bayer HealthCare AG
    Inventors: Johannes-Peter Stasch, Mathias Gehrmann, Berthold Hocher
  • Tetrahydro-naphthalene and urea derivatives
    Publication number: 20070167458
    Abstract: This invention relates to a hydroxy-tetrahydro-naphthalene or an urea derivative formula (I) and salts thereof which are useful as active ingredients of pharmaceutical preparations, wherein A represents formula (II) or (III) wherein # represents the connection position to the molecule and Q1a, Q2a, Q3a and Q4a are defined, and E represents formula (IV) or (V) wherein # represents the connection position to the molecule and Q1b, Q2b, Q3b, Q4b, Q5b, R1b, na, ma, Xa and Ra are defined.
    Type: Application
    Filed: September 22, 2004
    Publication date: July 19, 2007
    Applicant: BAYER HEALTHCARE AG
    Inventors: Axel Bouchon, Nicole Diedrichs, Achim Hermann, Klemens Lustig, Heinrich Meier, Josef Pernerstorfer, Elke Reissmuller, Jean De Vry, Muneto Mogi, Klaus Urbahns, Takeshi Yura, Hiroshi Fujishima, Masaomi Tajimi, Noriyuki Yamamoto, Hiroaki Yuasa, Jang Gupta, Yasuhiro Tsukimi, Fumihiko Hayashi
  • 6-Arylmethyl-substituted pyrazolopyrimidines
    Publication number: 20070161662
    Abstract: The invention relates to novel 6-arylmethyl-substituted pyrazolopyrimidines, process for their preparation and their use for producing medicaments for improving perception, concentration, learning and/or memory.
    Type: Application
    Filed: April 27, 2004
    Publication date: July 12, 2007
    Applicant: Bayer HealthCare AG
    Inventors: Martin Hendrix, Lars Barfacker, Christina Erb, Frank-Thorsten Hafner, Heike Heckroth, Dagmar Karthaus, Adrian Tersteegen, Franz-Josef van der Staay, Marja van Kampen
  • Method for producing 5-chloro-n-({(5s)-2-oxo-3-[4-(3-oxo-4-morpholinyl)phenyl]-1,3-oxazolidin-5-yl}methyl)-2-thiophenecarboxamide
    Publication number: 20070149522
    Abstract: The invention relates to a method for producing 5-chloro-N-({5S)-2-oxo-3-[4-(3-oxo-4-morpholinyl)-phenyl]-1,3-oxazolidin-5-yl}-methyl)-2-thiophene carboxamide starting from 5-chlorothiophene-2-carbonyl chloride, (2S)-3-amino-propane-1,2-diol and 4-(4-aminophenyl)-3-morpholinone.
    Type: Application
    Filed: December 24, 2003
    Publication date: June 28, 2007
    Applicant: Bayer Healthcare AG
    Inventor: Christian Thomas
  • Indole-phenylsulfonamide derivatives used as ppar-delta activating compounds
    Publication number: 20070149514
    Abstract: The invention relates to novel indole-phenylfulfonamide derivatives, to methods for the production thereof, and to their use in medicaments, particularly as potent PPAR-delta activating compounds, for the prevention and/or treatment of cardiovascular diseases, particularly dyslipidemias and coronary heart diseases.
    Type: Application
    Filed: December 24, 2003
    Publication date: June 28, 2007
    Applicant: Bayer HealthCare AG
    Inventors: Michael Woltering, Hilmar Bischoff, Elke Dittrich-Wengenroth, Heike Heckroth, Michael Otteneder
  • Diagnostics and therapeutics for diseases associated with kallikrein 12 (klk12)
    Publication number: 20070148175
    Abstract: The invention provides a human KLK12 which is associated with the gastrointestinal and liver diseases, cancer disorders, hematological diseases, inflammatory diseases, respiratory diseases, neurological disorders, cardiovascular disorders, reproduction disorders and urological disorders. The invention also provides assays for the identification of compounds useful in the treatment or prevention of gastrointestinal and liver diseases, cancer disorders, hematological diseases, inflammatory diseases, respiratory diseases, neurological disorders, cardiovascular disorders, reproduction disorders and urological disorders. The invention also features compounds which bind to and/or activate or inhibit the activity of KLK12 as well as pharmaceutical compositions comprising such compounds.
    Type: Application
    Filed: January 15, 2005
    Publication date: June 28, 2007
    Applicant: Bayer Healthcare ag
    Inventors: Stefan Golz, Ulf Bruggemeier, Andreas Geerts, Holger Summer
  • 2786, a novel human aminopeptidase
    Patent number: 7235634
    Abstract: The present invention relates to a newly identified human aminopeptidase. The invention also relates to polynucleotides encoding the aminopeptidase. The invention further relates to methods using the aminopeptidase polypeptides and polynucleotides as a target for diagnosis and treatment in aminopeptidase-related disorders. The invention further relates to drug-screening methods using the aminopeptidase polypeptides and polynucleotides to identify agonists and antagonists for diagnosis and treatment. The invention further encompasses agonists and antagonists based on the aminopeptidase polypeptides and polynucleotides. The invention further relates to procedures for producing the aminopeptidase polypeptides and polynucleotides.
    Type: Grant
    Filed: January 29, 2004
    Date of Patent: June 26, 2007
    Assignee: Bayer HealthCare AG
    Inventors: Rosana Kapeller-Libermann, David White, Kyle J. MacBeth
  • Diagnostics and therapeutics for diseases associated with endothelial differentiation, sphingolipid g-protein-coupled receptor 6(edg6)
    Publication number: 20070141571
    Abstract: The invention provides a human EDG6 which is associated with the cardiovascular disorders, gastrointestinal and liver diseases, inflammatory diseases, hematological disorders, respiratory diseases, neurological disorders, urological disorders, thrombocytopenia and myeloma. The invention also provides assays for the identification of compounds useful in the treatment or prevention of cardiovascular disorders, gastrointestinal and liver diseases, inflammatory diseases, hematological disorders, respiratory diseases, neurological disorders, urological disorders, thrombocytopenia and myeloma. The invention also features compounds which bind to and/or activate or inhibit the activity of EDG6 as well as pharmaceutical compositions comprising such compounds.
    Type: Application
    Filed: March 17, 2004
    Publication date: June 21, 2007
    Applicant: BAYER HEALTHCARE AG
    Inventors: Stefan Golz, Ulf Bruggemeier, Andreas Geerts
  • Dihydropyridinone derivatives
    Patent number: 7230017
    Abstract: The invention relates to novel dihydropyridinone derivatives, processes for their preparation, and their use in medicaments, especially for the treatment of chronic obstructive pulmonary diseases, acute coronary syndrome, acute myocardial infarction and heart failure development.
    Type: Grant
    Filed: August 18, 2003
    Date of Patent: June 12, 2007
    Assignee: Bayer Healthcare AG
    Inventors: Heike Gielen-Haertwig, Volkhart Min-Jian Li, Ulrich Rosentreter, Karl-Heinz Schlemmer, Swen Allerheiligen, Leila Telan, Lars Bärfacker, Jörg Keldenich, Mary F. Fitzgerald, Kevin Nash, Barbara Albrecht, Dirk Meurer
  • Antibacterial amide macrocycles
    Publication number: 20070129288
    Abstract: The invention relates to antibacterial amide macrocycles, to methods for the production thereof, and to the use of the same for producing pharmaceuticals for the treatment and/or prophylaxis of illness, especially bacterial infections.
    Type: Application
    Filed: June 10, 2003
    Publication date: June 7, 2007
    Applicant: BAYER HEALTHCARE AG
    Inventors: Thomas Lampe, Isabelle Adelt, Dieter Beyer, Nina Brunner, Rainer Endermann, Kerstin Ehlert, Heinz-Peter Kroll, Franz Nussbaum, Siegfried Raddatz, Joachim Rudolph, Guido Schiffer, Andreas Schumacher, Yolanda Canco-Grande, Martin Michels, Stefan Weigand
  • Diagnostic and therapeutics for diseases associated with 5-hydroxytryptamine (serotonin) receptor 7 (5-ht7)
    Publication number: 20070128603
    Abstract: The invention provides a human 5-HT7 which is associated with the cardiovascular disorders, dermatological disorders, gastrointestinal and liver diseases, cancer disorders, inflammatory diseases, metabolic diseases, hematological disorders, respiratory diseases, neurological disorders and urological disorders. The invention also provides assays for the identification of compounds useful in the treatment or prevention of cardiovascular disorders, dermatological disorders, gastrointestinal and liver diseases, cancer disorders, inflammatory diseases, metabolic diseases, hematological disorders, respiratory diseases, neurological disorders and urological disorders. The invention also features compounds which bind to and/or activate or inhibit the activity of 5-HT7 as well as pharmaceutical compositions comprising such compounds.
    Type: Application
    Filed: May 15, 2004
    Publication date: June 7, 2007
    Applicant: BAYER HEALTHCARE AG
    Inventors: Stefan Golz, Ulf Bruggemeier, Andreas Geerts
  • Bicyclic indolinesulphonamide derivatives
    Publication number: 20070117860
    Abstract: The invention relates to novel bicyclic indoline sulfonamide derivatives of general formula (I), methods for the production thereof, and the use thereof in medicaments, especially as potent PPAR delta agonists for preventing and/or treating cardiovascular diseases, particularly dyslipidemia, arteriosclerosis, and coronary heart diseases.
    Type: Application
    Filed: July 20, 2004
    Publication date: May 24, 2007
    Applicant: BAYER HEALTHCARE AG
    Inventors: Elke Dittrich-Wengenroth, Hilmar Bischoff, Stephan Siegel, Michael Woltering
  • Regulation of novel human asparagine-hydroxylases
    Publication number: 20070117142
    Abstract: Reagents that regulate human asparagine-hydroxylase and reagents which bind to human asparagine-hydroxylase gene products can play a role in preventing, ameliorating, or correcting dysfunctions or diseases including, but not limited to cardiovascular disorders, anaemia, cancer, inflammatory diseases, fibrotic disorders, and CNS disorders.
    Type: Application
    Filed: December 19, 2006
    Publication date: May 24, 2007
    Applicant: Bayer Healthcare AG
    Inventors: Ingo Flamme, Felix Oehme, Peter Ellinghaus
  • Determination of free fractions
    Publication number: 20070111208
    Abstract: The invention relates to methods for the determination of pharmacological properties of substances, such as, e.g., chemical substances. The invention also relates to methods and kits for use in the determination of the free fraction, fu, of pharmaco-logically active compounds in aqueous solutions and serum. The invention also relates to the above methods in which solid particles, coated with a lipophilic medium, are used.
    Type: Application
    Filed: August 4, 2004
    Publication date: May 17, 2007
    Applicant: Bayer HealthCare AG
    Inventors: Joachim Schuhmacher, Christian Kohlsdorfer
  • 6-Arylamino-5-cyano-4-pyrimidinones as pde9a inhibitors
    Publication number: 20070105881
    Abstract: The invention relates to novel 6-arylamino-5-cyano-4-pyrimidinones of formula (I) methods for the production thereof, and the use thereof for producing medicaments utilized for improving awareness, concentration, learning capacity, and/or retentiveness of memory. Said compounds (I) show activity as PDE9 inhibitors.
    Type: Application
    Filed: June 16, 2004
    Publication date: May 10, 2007
    Applicant: Bayer HealthCare AG
    Inventors: Martin Hendrix, Lars Barfacker, Bettina Beyreuther, Ulrich Ebert, Christina Erb, Frank-Thorsten Hafner, Heike Heckroth, Yan-Hong Liu, Dagmar Karthaus, Adrian Tersteegen, Franz-Josef van der Staay, Marja van Kampen
  • Diagnostics and therapeutics for diseases associated with g-protein-coupled receptor ltb4 (ltb4)
    Publication number: 20070105104
    Abstract: The invention provides a human LTB4 which is associated with the cardiovascular disorders, endocrine system and hormone disorders, metabolic diseases, gastrointestinal and liver diseases, hematological disorders, respiratory diseases, neurological disorders and urological disorders. The invention also provides assays for the identification of compounds useful in the treatment or prevention of cardiovascular disorders, endocrine system and hormone disorders, metabolic diseases, gastrointestinal and liver diseases, hematological disorders, respiratory diseases, neurological disorders and urological disorders. The invention also features compounds which bind to and/or activate or inhibit the activity of LTB4 as well as pharmaceutical compositions comprising such compounds.
    Type: Application
    Filed: April 24, 2004
    Publication date: May 10, 2007
    Applicant: BAYER HEALTHCARE AG
    Inventors: Stefan Golz, Ulf Bruggemeier, Holger Summer
  • Diagnostics and therapeutics for diseases associated with n-acetylated alpha-linked acidic dipeptidase 2(naaladase 2)
    Publication number: 20070099255
    Abstract: The invention provides a human NAALADASE 2 which is associated with the cardiovascular diseases, dermatological diseases, gastroenterological diseases, cancer, hematological diseases, neurologcial diseases, urological diseases, respiratory diseases and reproduction disorders. The invention also provides assays for the identification of compounds useful in the treatment or prevention of cardiovascular diseases, dermatological diseases, gastroenterological diseases, cancer, hematological diseases, neurological diseases, urological diseases, respiratory diseases and reproduction disorders. The invention also features compounds which bind to and/or activate or inhibit the activity of NAALADASE 2 as well as pharmaceutical compositions comprising such compounds.
    Type: Application
    Filed: October 12, 2004
    Publication date: May 3, 2007
    Applicant: BAYER HEALTHCARE AG
    Inventors: Stefan Golz, Ulf Bruggemeier, Andreas Geerts, Stefanie Polej
  • Combination of acetylsalicylic acid and alpha-glucosidase inhibitors
    Publication number: 20070099850
    Abstract: The invention relates to a combination of acetylsalicylic acid (component A) with an alpha-glucosidase inhibitor (component B) for the prevention of cardiovascular disorders.
    Type: Application
    Filed: May 15, 2004
    Publication date: May 3, 2007
    Applicant: BAYER HEALTHCARE AG
    Inventors: Gilbert Wagener, Khairy Elmahdi, Uwe Hohner